- Home
- KOSS vs ANL Comparison
KOSS vs ANL Comparison
Compare KOSS & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KOSS | ANL |
|---|---|---|
| Founded | 1953 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.6M | 52.0M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | KOSS | ANL |
|---|---|---|
| Price | $4.59 | $0.88 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 23.9K | 13.2K |
| Earning Date | 10-30-2025 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,493,080.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.58 | N/A |
| 52 Week Low | $4.00 | $0.88 |
| 52 Week High | $8.59 | $2.99 |
Technical Indicators
Market Signals| Indicator | KOSS | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 43.10 | 22.30 |
| Support Level | $4.80 | $1.32 |
| Resistance Level | $4.99 | $1.59 |
| Average True Range (ATR) | 0.19 | 0.16 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 24.86 | 5.70 |
Price Performance
Historical ComparisonAbout KOSS Koss Corporation
Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones. The Company also sells products to distributors for resale to school systems, and directly to other manufacturers for inclusion with their own products.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.